CRL
NEUTRALEarningsCharles River Laboratories Inte
This is the 2026-09-01 snapshot — the signals and analysis for CRL as of this single trading day.
View full CRL research hub →Analysis
CRL is exhibiting High-Conviction Price Discovery, surging over 20% this past month driven by a Q2 earnings beat, raised 2026 guidance, and a newly announced vaccine partnership with Medigen. Technical signals like the PERFECT_STACK and GOLDEN_CROSS validate this fundamental strength, showing strong institutional accumulation despite today's minor low-volume pullback. Furthermore, the resilient RISK_ON macro regime—evidenced by tight credit spreads and a subdued VIX despite Middle East geopolitical shocks—creates an ideal backdrop for capital to rotate into insulated, high-relative-strength life science leaders. Today's 2% dip on 0.8x volume is a textbook digestion phase being absorbed by structural buyers rather than a trend reversal.
Fired Signals
Key Takeaways
- Actionable Thesis: Accumulate shares during this light-volume pullback, utilizing the $260.72 support level as a firm risk-management backstop to ride the GOLDEN_CROSS momentum.
- Key Risk: A broader macro liquidity shock if Middle East geopolitical tensions escalate enough to widen credit spreads, which could drag down high-beta growth equities.
- What to Watch: Continued relative strength versus the SPY and execution updates regarding their Discovery and Safety Assessment (DSA) demand and AI/ML partnerships.